Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2002-01-11
2009-11-10
Chen, Shin-Lin (Department: 1632)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023100, C530S350000
Reexamination Certificate
active
07615622
ABSTRACT:
The present invention provides methods of increasing the half-life factor VIII. More specifically, the invention methods of increasing the half-life of factor VIII by substituting amino acids in the A2 domain or in the C2 domain of factor VIII or in both domains. It further provides factor VIII mutants produced by these methods. The invention also provides a method of using receptor-associated protein (RAP) to increase the half-life of factor VIII. The invention also provides polynucleotides encoding the mutant factor VIII, polynucleotides encoding RAP, and methods of treating hemophilia using the polypeptides and polynucleotides of the invention.
REFERENCES:
patent: 4757006 (1988-07-01), Toole, Jr. et al.
patent: 4868112 (1989-09-01), Toole, Jr.
patent: 4965199 (1990-10-01), Capon et al.
patent: 5004803 (1991-04-01), Kaufman et al.
patent: 5364771 (1994-11-01), Lollar et al.
patent: 5583209 (1996-12-01), Lollar et al.
patent: 5650391 (1997-07-01), Schwartz et al.
patent: 5663060 (1997-09-01), Lollar et al.
patent: 5681746 (1997-10-01), Bodner et al.
patent: 5744446 (1998-04-01), Lollar et al.
patent: 5859204 (1999-01-01), Lollar
patent: 5888974 (1999-03-01), Lollar et al.
patent: 6083905 (2000-07-01), Voorberg et al.
patent: 6180371 (2001-01-01), Lollar
patent: 6376463 (2002-04-01), Lollar
patent: 6458563 (2002-10-01), Lollar
patent: 6838437 (2005-01-01), Kaufman et al.
patent: 2003/0068785 (2003-04-01), Lollar
patent: 2003/0166536 (2003-09-01), Lollar
patent: 2205824 (1997-05-01), None
patent: WO 87/04187 (1987-07-01), None
patent: WO 88/03558 (1988-05-01), None
patent: WO 88/08035 (1988-10-01), None
patent: WO 93/20093 (1993-10-01), None
patent: WO 94/11503 (1994-05-01), None
patent: WO 95/18827 (1995-07-01), None
patent: WO 97/03195 (1997-01-01), None
patent: WO 97/49725 (1997-12-01), None
patent: WO 00/27425 (2000-05-01), None
patent: WO 00/28021 (2000-05-01), None
patent: WO 00/71714 (2000-11-01), None
patent: WO 02/060951 (2002-08-01), None
Celie et al., 1999, British Journal of Haematology, vol. 106, p. 792-800.
Rudinger, 1976, Peptide Hormones, Parsons, University Park Press, Baltimore, p. 1-7.
Kaye et al., 1990, Proc. Natl. Acad. Sci. USA, vol. 87, pp. 6922-6926.
Skolnick et al., 2000, Trends in Biotech, vol. 18, p. 34-39.
Davis, C. G., 1990, The New Biologist, vol. 2, No. 5, p. 410-419.
Church, W.R., et al., “Coagulation factors V and VIII and ceruloplasmin constitute a family of structurally related proteins,”Proc. Natl. Acad. Sci. USA 81:6934-6937, National Academy of Science (1984).
Pass, D.N., et al., “Monoclonal Antibodies to Porcine Factor VIII Coagulant and Their Use in the Isolation of Active Coagulant Protein,”Blood 59:594-600, Grune & Stratton (1982).
Gitschier, J., et al., “Characterization of the human factor VIII gene,”Nature 312:326-330, Macmillan Publishers (1984).
Herz, J., et al., “Surface location and high affinity for calcium of 500-kd liver membrane protein closely related to the LDL-receptor suggest a physiological role as lipoprotein receptor,”EMBO J. 7:4119-4127, IRL Press Ltd. (1988).
Ho, G., et al., “Receptor-mediated Endocytosis of Coagulation Factor Xa Requires Cell Surface-bound Tissue Factor Pathway Inhibitor,”J. Biol. Chem. 271:9497-9502, The American Society for Biochemistry and Molecular Biology, Inc. (1996).
Knauer, M.F., et al., “Identification of a Binding Site in Protease Nexin I (PN1) Required for the Receptor Mediated Internalization of PN1-Thrombin Complexes,”J. Biol. Chem. 272:12261-12264, The American Society for Biochemistry and Molecular Biology, Inc., (1997).
Kounnas, M.Z., et al., “Cellular Internalization and Degradation of Antithrombin III-Thrombin, Heparin Cofactor II-Thrombin, and α1-Antitrypsin-Trypsin Complexes Is Mediated by the Low Density Lipoprotein Receptor-related Protein,”J. Biol. Chem. 271:6523-6529, The American Society for Biochemistry and Molecular Biology (1996).
Mikhailenko, I., et al., “Cellular Internalization and Degradation of Thrombospondin-1 Is Mediated by the Amino-terminal Heparin Binding Domain (HBD),”J. Biol. Chem. 272:6784-6791, The American Society for Biochemistry and Molecular Biology, (1997).
Moestrup, S.K., et al., “Distribution of the α2-macroglobin receptor/low density lipoprotein receptor-related protein in human tissues,”Cell Tissue Res. 269:375-382, Springer-Verlag (1992).
Moestrup, S.K., et al., “α2-Macroglobulin-Proteinase Complexes, Plasminogen Activator Inhibitor Type-1-Plasminogen Activator Complexes, and Receptor-associated Protein Bind to a Region of the α2-Macroglobulin Receptor Containing a Cluster of Eight Complement-type Repeats,”J. Biol. Chem. 268:13691-13696, The American Society for Biochemistry and Molecular Biology (1993).
Moestrup S.K., “The α2-macroglobulin receptor and epithelial glycoprotein-330: two giant receptors mediating endocytosis of multiple ligands,”Biochim. et Biophys. Acta. 1197:197-213, Elsevier Science B.V. (1994).
Narita, M., et al., “The Low-Density Lipoprotein Receptor-Related Protein (LRP) Mediates Clearance of Coagulation Factor Xa in Vivo,”Blood 91:555-560, W.B. Saunders Company (Jan. 1998).
Nykjaer, A., et al., “Purified α2-Macroglobulin Receptor/LDL Receptor-related Protein Binds Urokinase Plasminogen Activator Inhibitor Type-1 Complex,”J. Biol. Chem. 267:14543-14546, The American Society for Biochemistry and Molecular Biology (1992).
Orth, K., et al., “Complexes of tissue-type plasminogen activator and its serpin inhibitor plasminogen-activator inhibitor type 1 are internalized by means of the low density lipoprotein receptor-related protein/α2-macroglobulin receptor,”Proc. Natl. Acad. Sci. USA 89:7422-7426, National Academy of Sciences (1992).
Saenko, E.L., et al., “Role of the Low Density Lipoprotein-related Protein Receptor in Mediation of Factor VIII Catabolism,”J. Biol. Chem. 274:37685-37692, The American Society for Biochemistry and Molecular Biology (Dec. 1999).
Strickland, D.K., et al., “Sequence Identity between the α2-Macroglobulin Receptor and Low Density Lipoprotein Receptor-related Protein Suggests That This Molecule Is a Multifunctional Receptor,”J. Biol. Chem: 265:17401-17404, The American Society for Biochemistry and Molecular Biology (1990).
Strickland, D.K., et al., “LDL receptor-related protein: a multiligand receptor for lipoprotein and preteinase catabolism,”FASEB J. 9:890-898, Federation of American Societies of Experimental Biology (1995).
Toole, J.J., et al., “Molecular cloning of a cDNA encoding human antihaemophilic factor,”Nature 312:342-347, Macmillan Publishers (1984).
Toole, J.J., et al., “A large region (=95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity,”Proc. Natl. Acad. Sci. USA 83:5939-5942, National Academy of Sciences (1986).
Vehar, G.A., et al., “Structure of human factor VIII,”Nature 312:337-342, Macmillan Publishers (1984).
Warshwsky, I., et al., “The low density lipoprotein receptor-related protein mediates the cellular degradation of tissue factor pathway inhibitor,”Proc. Natl. Acad. Sci. USA 91:6664-6668, National Academy of Sciences (1994).
Williams, S.E., et al., “A Novel Mechanism for Controlling the Activity of α2-Macroglobulin Receptor/Low Density Lipoprotein Receptor-related Protein,”J. Biol. Chem. 267:9035-9040, The American Society for Biochemistry and Molecular Biology (1992).
Wood, W.I., et al., “Expression of active human factor VIII from recombinant DNA clones,”Nature 312:330-337, Macmillan Publishers (1984).
Yakhyaev, A., et al., “Cellular uptake and degradation of the thrombin activated factor VIII fragments,”Blood 90:31a, Abstract No. 126, W.B. Saunders Company (1997).
Dialog File 351, Accession No. 11425054, Derwent WPI English language abstract for EP 0 808 901 A2.
Saenko Evgueni L.
Sarafanov Andrey G
Chen Shin-Lin
Sughrue & Mion, PLLC
University of Maryland Baltimore
LandOfFree
Methods and compositions for reducing heparan sulfate... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for reducing heparan sulfate..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for reducing heparan sulfate... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4115364